EF Hutton Reiterates Buy on Sonnet BioTherapeutics, Maintains $6.7 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Michael King reiterates a Buy rating on Sonnet BioTherapeutics (NASDAQ:SONN) and maintains a $6.7 price target.
June 26, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Michael King reiterates a Buy rating on Sonnet BioTherapeutics and maintains a $6.7 price target.
The reiterated Buy rating and maintained price target by EF Hutton analyst Michael King indicates a positive outlook for Sonnet BioTherapeutics. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100